Valsartan And Hydrochlorothiazide Tablet, Film Coated
Product Images NDC 51655-698

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Valsartan And Hydrochlorothiazide (NDC 51655-698). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label (51655 698 52 Master Bottle Label Approval Rev A 03 21)

Label (51655 698 52 Master Bottle Label Approval Rev A 03 21)
NDC: 51655-698-52 Valsartan and Hydrochlorothiazide Tablets, USP 160mg/12.5mg, 30 Tablets, Rx Only. The package insert contains dosage information and storage instructions. Store at 2-25°C (68-77°F) with excursions permitted to 15°-30°C (59°-86°F). The medication should be kept out of the reach of children and stored in the original container to protect from moisture. The tablet is film-coated and contains 160mg of Valsartan and 12.5mg of Hydrochlorothiazide. This medication has been repackaged by Northwind Pharmaceuticals with serial number 000000000000000. The lot number is 0000000000 with an expiration date of 00/00/0000. The manufacturer is Macleods Pharma USA, Inc. This information is useful for those considering using or dispensing this medication.*
FDA Label Image

Figure-1 (Valsartan Hctz Figure 1)

Figure-1 (Valsartan Hctz Figure 1)
This text is describing a table showing the baseline systolic blood pressure (SBP) levels in mmHg for a study involving different medications for hypertension. The medications listed are Valsartan HCT 320/25mg, Amlodipine/Valsartan 10/320mg, Valsartan 320mg, Hydrochlorothiazide 25mg, and Placebo. The table also includes readings of SBP ranges from 140 to 180 mmHg.*
FDA Label Image

Figure-2 (Valsartan Hctz Figure 2)

Figure-2 (Valsartan Hctz Figure 2)
This appears to be a table showing the results of a study evaluating blood pressure medication. The medications tested were valsartan HCT 320/25 mg, AAA valsartan 320 mg, hydrochlorothiazide 25 mg, and a placebo. The data presented shows the baseline diastolic blood pressure (DBP) at 105 mmHg, and the goal was to reduce it to below 90 mmHg. However, without more information, it is difficult to provide a more detailed description of the study and its outcomes.*
FDA Label Image

Figure-3 (Valsartan Hctz Figure 3)

Figure-3 (Valsartan Hctz Figure 3)
FDA Label Image

Figure-4 (Valsartan Hctz Figure 4)

Figure-4 (Valsartan Hctz Figure 4)
This is a chart showing the baseline diastolic blood pressure (DBP in mmHg) readings for patients taking Valsartan HCT 320/125 mg or Valsartan 320 mg along with Hydrochlorothiazide 25 mg versus a placebo. The readings range from 95 mmHg to 105 mmHg.*
FDA Label Image

Hctz-stru (Valsartan Hctz Hydrochlorothiazide)

Hctz-stru (Valsartan Hctz Hydrochlorothiazide)
FDA Label Image

Valsartan-str (Valsartan Hctz Valsartan)

Valsartan-str (Valsartan Hctz Valsartan)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.